STAT3 and non-small cell lung carcinoma: It was demonstrated that RO4929097 (1–10 μmol/L) with or without cisplatin modulated the self-renewing activity of LCSCs via p-STAT3 and HES1 in human non-small cell lung cancer (NSCLC) cells, whereas RO4929097 treatment increased their platinum resistance.